Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.

Wu J, Zhang S, Yu S, An G, Wang Y, Yu Y, Liang L, Wang Y, Xu X, Xiong Y, Shao D, Shi Z, Li N, Wang J, Jin D, Liu T, Cui Y

Open source

DOI: 10.1038/s41467-024-53109-4
Published: 2024 Oct 15
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-024-53109-4,
  title = {Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.},
  author = {Wu J and Zhang S and Yu S and An G and Wang Y and Yu Y and Liang L and Wang Y and Xu X and Xiong Y and Shao D and Shi Z and Li N and Wang J and Jin D and Liu T and Cui Y},
  year = {2024},
  journal = {Nature communications},
  doi = {10.1038/s41467-024-53109-4},
  url = {https://doi.org/10.1038/s41467-024-53109-4}
}

RIS

TY  - JOUR
TI  - Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.
AU  - Wu J
AU  - Zhang S
AU  - Yu S
AU  - An G
AU  - Wang Y
AU  - Yu Y
AU  - Liang L
AU  - Wang Y
AU  - Xu X
AU  - Xiong Y
AU  - Shao D
AU  - Shi Z
AU  - Li N
AU  - Wang J
AU  - Jin D
AU  - Liu T
AU  - Cui Y
PY  - 2024
JO  - Nature communications
DO  - 10.1038/s41467-024-53109-4
UR  - https://doi.org/10.1038/s41467-024-53109-4
ER  -

APA

J, W., S, Z., S, Y., G, A., Y, W., Y, Y., L, L., Y, W., X, X., Y, X., D, S., Z, S., N, L., J, W., D, J., T, L., & Y, C. (2024). Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.. Nature communications. https://doi.org/10.1038/s41467-024-53109-4

Source records

pubmed · retrieved 2026-09-25T23:12:37.165Z